Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 6

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 17Thoracic 8Tumor-Agnostic 6Gynecologic 4Breast 4Other solid neoplasm 3Sarcoma 2Other neoplasm 1Genitourinary 1

Conditions

Neoplasms 5Neoplasm Metastasis 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × apatinib × Tumor-Agnostic × Clear all
NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
543 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03396211 2023-04-07

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Elevar Therapeutics

Phase 1 Completed
30 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01192971 2023-03-03

HCC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
121 enrolled
Tumor-Agnostic

Neoplasms

NCT01497704 2017-10-02

Dose-Escalation and Safety Trial of YN968D1

Elevar Therapeutics

Phase 1/2 Completed
55 enrolled
Tumor-Agnostic

Neoplasms

NCT02836171 2017-02-27

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

NCT02836821 2017-02-27

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡